One of the major contributions of the wartime malaria research program was the development of a number of synthetic antimalarial drugs with suppressive activity superior to that of quinacrine. Of the various chemical compounds examined, certain derivatives of 4-aminoquinoline are among the more promising.
The 4-aminoquinolines had been considered as potentially useful antimalarial agents prior to the war and, in fact, a number appear in the patent literature. Translated abstracts of the Russian literature deal with several members of this series (1) . However, there is little evidence that these compounds had received adequate pharmacological, toxicological, or clinical study. One 4-aminoquinoline, SN-6911 (santochin), had been studied early in the course of the systematic survey of antimalarials in this country and had shown high activity in gallinaceum malaria in the chick (2, 3) . However, the lead suggested by this observation was not appreciated at the time.
It was not until the French found SN-6911 to be well tolerated and to have high activity in the human malarias that a serious effort was made, in this country, to explore the 4-aminoquinoline se- A large number of derivatives of 4-aminoquinoline have since been synthesized. These were examined for antimalarial activity in avian malarias and the most active were subjected to mammalian toxicity studies. The ten compounds shown in Table I have received trial in the human. It is the purpose of the present communication to report on studies of the physiological disposition, antimalarial activity and toxicity of several of these compounds. 98 1. The conversion of a non-fluorescent 4-aminoquinoline to a highly fluorescent substance by irradiation with near ultraviolet light (6) . This is accomplished by irradiation of the compounds in an aqueous solution at pH 9.5 in the presence of cysteine to prevent further oxidation of the fluorophore formed. Several of the 4-aminoquinolines appear to yield the same fluorophore, since all of the compounds estimated with this procedure have the same relationship between quinoline concentration and intensity of fluorescence. This method was used for the estimation of SN-7618, 8137, 10,751, 7135, 13,425.
2. The formation of an organic-soluble, water-insoluble complex of the 4-aminoquinoline with methyl orange (7) . This procedure was used for the estimation of SN-6911 only. The conversion of SN-6911 to a fluorophore requires radiant energy of a lower wavelength than was readily available. However, the rather high plasma drug concentrations obtained permitted the use of the less sensitive methyl orange reaction.
3. The direct measurement of fluorescence in an organic solvent (8) . This method was used for the estimation of SN-3294 since the compound itself is highly fluorescent.
The evidence available indicated that the methods used for estimating the concentrations of the 4-aminoquinolines in biological materials are reliable and, in general, highly specific. The SN-3294 and SN-10,751 methods are exceptions in that certain metabolic products of the drugs are included in the final determination.
Section I PHYSIOLOGICAL DISPOSITION
The data presented in this section describe some of the important aspects of the physiological disposition of the 4-aminoquinolines. Each compound was studied to obtain information relative to absorption from the gastro-intestinal tract, renal excretion, distribution in various tissues, binding on the non-diffusible constituents of plasma, and the effect of these discrete processes in determining the relationship between oral dosage and plasma drug concentration. Absorption and excretion were examined in balance studies in which the subjects received a soluble salt of a drug over a period of days until plasma drug concentrations had become stable. Urine and stool collections were made during the last 48-hour period of drug administration (Table  II) . The small amount of drug recovered from the stools in each instance indicates fairly complete absorption from the gastro-intestinal tract. At equilibrium the urinary excretion, under ordinary conditions, accounts for 10 to 25 per cent of the daily oral dose. However, the rate of renal excretion can be made to vary over a wide range by the concurrent administration of acid or alkali, being increased by acid and decreased by alkali. Detailed studies relating acid-base balance and the physiological disposition of the 4-aminoquinolines are reported in a separate communication (9) .
Data on the distribution of two compounds (SN-3294 and SN-7618) in the body fluids and bound to a considerable extent to the nondiffusible constituents of plasma, although SN-10,751 alone is bound to as great a degree as quinacrine. The percentage of drug bound in vitro varies widely and systematically with variation in pH, but it is doubtful that changes of practical importance occur within the restricted physiological range of pH observed in the human.
The plasma concentration of a chemotherapeutic agent, reflecting the oral dosage and the discrete physiological processes of absorption, distribution, metabolic degradation and excretion, provides a convenient means for following its over-all disposition. In addition, information describing the relationship between oral dosage and plasma drug concentration is necessary in the design of rational regimens of therapy. Data of this type, on each of the 4-aminoquinolines studied, are summarized in Table V The values for activity obtained in these studies are not considered to be directly applicable to all strains of plasmodia. However, the tests in bloodinduced infections utilized strains of P. zivax (McCoy) and P. falciparum (McClendon) whose susceptibility to quinine and quinacrine is known (12, 13, 14) . The testing procedures have been demonstrated to yield reproducible results which define the chemotherapeutic susceptibilities of various strains. Consequently, the activity of related compounds may be compared and related to that of either quinine or quinacrine. Antimalarial activity assayed in this manner is probably a true measure of the ability of an agent to suppress, and to cure, naturally-occurring falciparum malaria and to suppress naturally-occurring vivax malaria.
Procedure. All of the therapeutic tests with bloodinduced malaria were performed in accordance with standard procedures previously outlined (12, 13) . The regimens of dosage were designed to produce fairly stable plasma drug concentrations during the four-day (vivax) or six-day (falciparum) therapeutic period as in the quinacrine studies (14) . Therapeutic results are classified in three groups as previously defined: Class I, no certain effect; Class II, temporary suppression of parasitemia and/or fever; Class III, "permanent" effect, i.e., absence of parasitemia for 14 days (vivax) or 21 days (falciparum) followed by a positive reinoculation to indicate continued host-susceptibility to the infection. The separation of Class II and Class III effects must take into consideration the tendency of these drugs to persist beyond the termination of therapy. The conventions adopted in the design of therapeutic tests in such a situation have been discussed elsewhere (14) .
Seven derivatives of 4-aminoquinoline have been tested for their effects on blood-induced infections with the McCoy strain of P. vivax. The results are presented in Table VII. 1. SN-3294. The study of this drug was limited to observations in eight patients because of its low antimalarial activity. It is the least active of the drugs, as judged either by the oral dosage or by the plasma drug concentration required to produce a given therapeutic effect. The smallest total oral dose which resulted in a Class II effect was 2.1 grams, while doses as large as 1.2 grams failed to exert any certain effect in two of the patients. The lowest mean plasma drug concentration producing a Class III effect appear to be in the same order in the two infections.
At a later date, and after information on the toxicity of these compounds was at hand, further study of their potential use in the routine suppression of malaria was undertaken. These experiments were designed to test the relative effectiveness of three of the more promising members of the group under experimental conditions simulating the use of the drugs as suppressives in the field. They were examined for their suppressive activity in mosquito-induced malaria due to the Chesson strain of P. zpivax. Chesson vivax malaria differs from McCoy in at least two important respects: (1) The erythrocytic parasites are considerably less susceptible to the-action of quinine or quinacrine, and (2) the mosquito-induced infections are characterized-by frequent true relapses beginning as early as one week after the termination of a full course of quinine therapy.
Thirty volunteer subjects 6 were distributed at random into three equal groups. The drugs were administered in single doses of 0.25 gram once weekly for a total of four doses. Malaria was induced by the bites of A. quadrimaculatus mosquitoes infected with the Chesson strain of P. uivax. Each subject was bitten on three alternate days beginning one week after the first dose of drug, i.e., on the first, third, and fifth days of the second week of drug administration. Subsequent to biting, the salivary glands of the mosquitoes were dissected out, examined for the presence of sporozoites, and the positive glands graded 1 to 4 plus. The inocula, expressed as the total infection densities of mosquitoes biting each subject, ranged from 24 plus to 56 plus with an average of 41 plus. Thick blood smears were examined daily until the appearance of parasites. Blood samples for the estimation of plasma drug concentrations were obtained before and four hours after each drug dose and on the day parasites first appeared in the blood.
The results of this study are summarized in Table IX . With the exception of one subject in the SN-6911 group, all of those exposed to the bites of mosquitoes eventually developed clinical malaria. Thick blood smears obtained between the 12th and 15th days after the first inoculation revealed small numbers of circulating parasites in three individuals in the SN-6911 group and three in the SN-8137 group. Fever did not accompany this demonstrable parasitemia. Thick blood smears failed to reveal parasitemia in any subject receiving SN-7618. However, when a suit-able technique for the concentration of parasitized erythrocytes was applied to blood samples obtained during this period, as was to be expected, circulating parasites could be demonstrated in all of the subjects in the three groups (15, 16) except for the one member of the SN-6911 group who never developed clinical malaria. It must be presumed that inoculation had been unsatisfactory in this case.
The shortest prepatent periods6 in the SN-6911 and SN-8137 groups were 24 and 26 days, respectively. With both of these drugs, parasitemia occurred consistently within 33 days, the average being 29 days. In the SN-7618 group, the shortest prepatent period was 43 days and the average, 50 days. In relation to the last dose of drug, the mean parasite-free intervals were 15 days for SN-6911 and SN-8137 and 36 days for SN-7618. The plasma drug concentrations of all three drugs at the end of the prepatent period were below the minimal effective suppressive level of the drug studied. It appears likely that a weekly dose of 0.25 gram of any one of the three drugs is close to the amount required to provide effective suppression against vivax malaria.
Section III
TOXICITY
The observations described in this section relate to the toxicity of some of the more promising of the 4-aminoquinolines. Five of the more active drugs were studied to determine the daily dose required to produce symptoms when each is administered in progressively increasing dosage.
Materials and methods
Sixty-four volunteers were distributed at random into four equal groups receiving, respectively, SN-7618, SN-8137, SN-9584, and SN-10,751. Thirty-two additional volunteers 5 were divided into two equal groups receiving SN-7618 and SN-13,425 respectively. 6 Transient parasitemias of low density are disregarded in this instance and the term "prepatent period" is used to indicate the interval from the first inoculation to the appearance of parasites at the onset of clinical malaria. 7 This study was conducted at the New Jersey State Reformatory, Rahway, New Jersey, with the cooperation of the late Commissioner W. J. Ellis and of Lieutenant W. E. Kulp. The subjects were young, healthy volunteers.
Each individual received an initial priming dose of the drug under study, followed by uniform dosage for a period of one week. The daily dose was increased in step-wise fashion at intervals of one week, each increase being preceded by a booster dose. The amount of drug administered each day was divided into two equal parts, and was taken in colorless capsules at 8 a.m. and 8 p.m. under direct supervision. All doses were calculated as the amount of the base administered. The schedule of dosage is shown in Table X . The desirability of reporting all symptoms was emphasized at the start of the study and an opportunity to report symptoms was offered at the time each dose was administered. However, in order to minimize the factor of suggestion, the subjects were not questioned as to the presence or absence of specific symptoms, except to follow up symptoms previously reported. Each individual was interviewed at the termination of the study and questioned in detail as to his general state of well-being. An attempt was made to elicit any symptoms which had been noted during the period of drug administration.
Adverse reactions There were sporadic complaints of various symptoms apparently unrelated to the medication throughout the period of the study. These symptoms were usually vague and followed no particular pattern in relation to the drug being taken by the individual. These complaints usually disappeared with the continued administration of increasing doses of medication. The symptoms of intoxication appeared later and showed striking uniformity within any one group. SN-10,751. Four of the 16 who received SN-10,751 were completely free of symptoms throughout the period of drug administration. Three others had minor complaints of brief duration at some time during the first three weeks of the study, but were free of symptoms during the final three weeks.
The symptoms noted in this group were somewhat ill-defined and non-specific and hence difficult to evaluate in the individual case. However, they did follow a fairly definite pattern and similar symptoms were relatively infrequent in the other groups during the latter part of the study.
Towards the end of the fourth week (300 mg. daily) eight men began to complain of lassitude, lack of energy, and inability to get to sleep at night. Several complained of a feeling of uneasiness in the epigastrium although they did not have definite nausea. Two individuals noted that, although they felt hungry between meals, their appetites disappeared on sitting down to eat. One other subject developed nausea and vomiting while receiving 200 mg. daily. This man had a past history of abdominal cramps and vomiting but it is interesting and possibly significant that the concentration of drug in his plasma was consistently the highest of any in the group.
Symptoms were sufficiently severe so that two men found it necessary to stop working during the last two weeks of the study and a third man refused further medication at the end of the fifth week. 425 . Six of the 16 men who received SN-13,425 were free of symptoms during the period of drug administration. Itching was the most frequent complaint among those volunteers who exhibited an intolerance to the drug. A total of seven subjects complained of generalized pruritus, four beginning in the third week, one during the fourth week, and two during the fifth week. A skin rash consisting of small, discrete, erythematous papules distributed over the arms, legs, buttocks and scrotum accompanied the itching in four subjects and persisted throughout the remaining period of drug administration.
During the fourth week, two of the subjects complained of nervousness and a third developed an acute anxiety state. The latter reaction was characterized by flushing of the face, extreme nervousness, insomnia and tremor, which continued for more than one week despite the immediate cessation of therapy. No significant eye symptoms were noted by the individuals receiving this drug.
DISCUSSION AND SUMMARY
The group of drugs derived from 4-aminoquinoline includes a number of compounds showing high antimalarial activity with potential usefulness in the treatment of human malaria. Changes in the nuclear substituents and changes in the character of the side chain are each accompanied by significant alterations in the physiological disposition, the antimalarial activity, and the toxicity of the resulting compounds.
The 4-aminoquinolines showing the most marked antimalarial activity in both avian and human malaria are derived from 7-chloro-4-aminoquinoline. The best combination of high activity and low toxicity was found in either or SN-8137. Both have advantages over quinacrine in their lower toxicity and in the smaller dosage or plasma drug concentration required to produce a given effect. Although SN-8137 is considerably less toxic than SN-7618, it is also somewhat less active. Administration of SN-7618 for over a year has shown it to be a safe suppressive agent when the recommended dosage is used (18) . Either drug is useful for routine suppression, but it would appear from the data derived from the field-type suppressive study that SN-7618 has a considerable margin of efficacy because of its greater activity and persistence. Dosage regimens which should be suitable for the suppression of malaria and for the treatment of acute attacks were chosen on the basis of the data presented in this paper. Work based on these suggested regimens has already been published (19, 20) and confirms the conclusions drawn from the experimental data. 
